Professor Peppas will be delivering a plenary lecture at the Annual Meeting in the fall, and text will be published in the Annals of Biomedical Engineering.
Professor Rebecca Richards-Kortum, Ph.D. (Rice University), received the 2016 Pierre Galletti Award from the American Institute for Medical and Biomedical Engineering (AIMBE). Professor Richards-Kortum was recognized for her leadership and innovation in the fields of global-health engineering and creating solutions that can save lives in low resource settings.
Academy and Society Inductions
Regenerative Engineering Society (RE Society) has been formally established under the American Institute of Chemical Engineers (AlChE). In honor of this, Regenerative Engineering Pioneers Plenary Session will be hold at the 
Views: Recent Advances in the Field

Advancements in Industry
Organovo, the California-based 3D biotech company, launched a collaboration with the University of California, San Francisco (UCSF) with the goal of developing advanced 3D bioprinted tissues for skeletal disease applications. This partnership has been funded by Methuselah, which previously funded Organovo's partnership with Yale for bioprinting transplant tissues. The use of 3D bioprinting will develop better in vitro models to investigate cures for musculoskeletal disorders which are the second leading cause of disabilities around the world.
Research and Markets forecasted that the global regenerative medicine market size will increase 20.7 % during 2016-2020 period. The market growth of regenerative medicine is driven by demand from patients and development of cell therapy, tissue engineering, and gene therapy.
Advancements in Academia
Scientists at the University of Toronto have designed and fabricated AngioChip, a biodegradable, perfusable scaffold that is able to generate both in vitro vascularized cardiac and hepatic tissue models in a scalable manner and in vivo implants with rapid and direct surgical anastomosis. This technology can overcome previous limitations in the field of tissue engineering to produce millimeter-sized tissues by inducing tissue endothelialization without delay while enable to integrate different tissues on a single device. This powerful platform technology was reported in Nature Materials.
Scientists at Columbia University have developed a maxillofacial reconstructive strategy by utilizing stem cells, decellularized bone and a perfusion bioreactor to overcome previous limitation of using autografts. Living grafts were engineered by using an image-guided personalized approach, and cells were cultured in perfusion in a bioreactor to form immature bone tissue. The engineered graft was successfully integrated with host tissue, formed new bone, and was vascularized extensively after implementation. This translational study was published in Science Translational Medicine.
Views: Government and Public Policy
President Obama announced his research and development plan of $200 million invested in public-private organizations in a new Advanced Tissue Biofabrication Manufacturing Innovation Institute in order to develop breakthrough technologies to replace and repair cells and tissues, which may eventually lead to complete organ replacements.
The National Aeronautics and Space Administration (NASA) and the Methuselah Foundation are holding a contest called the Vascular Tissue Challenge (Challenge) with a $500,000 prize for the first three groups of scientists who can create thick (>1 cm), perfusable human vascularized organ tissue in the laboratory, while maintaining high survival of parenchymal cells (>85 %) with metabolic functionality throughout a 30-calendar-day period. The human tissues created in the Challenge will be used for conducting research on human physiology, fundamental space biology, and medicine in the Earth and the International Space Station (ISS) National Laboratory.
The National Cell Manufacturing Consortium (NCMC) created a national roadmap to guide the path to develop large-scale, cost-effective cell-based therapy manufacturing technologies. This national roadmap will be used in the field of regenerative medicine to treat broad range of illness including cancer, neuro-degenerative diseases, and organ regeneration. Approximately 60 organizations from industry, academia, and government agencies have collaborated to design this roadmap.
